Search

Displaying results 5051 - 5060 of 9128 in total
  1. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  2. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  3. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  4. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  5. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  6. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

  7. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    It is administered as a 1 hour intravenous infusion every 3 weeks. … Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.

  8. Drug

    MEDI-547

    go.drugbank.com/drugs/DB18360
    Investigational

    MEDI-547 is an anti-EphA1 monoclonal antibody conjugated to mcMMAF

  9. Drug

    2G7

    go.drugbank.com/drugs/DB18589
    Experimental

    2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.

  10. Drug

    MGD-024

    go.drugbank.com/drugs/DB17265
    Investigational

    MGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.